AACR 2023 | RATIONALE-306: tislelizumab and chemotherapy in ESCC

Yongqian Shu, MD, PhD, Nanjing Medical University, Nanjing, China, presents findings from the Phase III RATIONALE-306 trial (NCT03783442) of tislelizumab with chemotherapy versus chemotherapy alone in patients with esophageal squamous cell carcinoma (ESCC). In the subgroup with patients from China, overall survival, progression-free survival, and overall response rate were all significantly superior in patients receiving tislelizumab and chemotherapy. An acceptable safety profile consistent with the overall cohort was additionally recorded. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.